戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 -44 d) and postoperative (18)F-FET PET (time after surgery: median, 14 d; range, 5-28 d) were included.
2 ecurrent tumors) who had preoperative (time before surgery: median, 23 d; range, 6-44 d) and postoperative (18)F-FET PET
3                                               After 12.8 y (median), 6378 participants had experienced a CHD event.
4                                            Of 614 patients (median age 69 years, (IQR 25) and 62% male), 381 (62%) had be
5                                                             Median age at HCT was 1.2 years.
6 pe-SCD occurred in 30 (53%) of 57 affected individuals at a median age of 22.5 years.
7                      A total of 480,940 middle-aged adults (median age of 58 years [range 38-73], 46% male, 95% white) we
8                                                         The median age of enrolled participants is 21 years (range 0-93 y
9                                           At enrolment, the median age was 15 years (IQR 14-17), 52% of adolescents were
10                                                         The median age was 49 (range, 18-86) years, and 62% were >= 40 ye
11 kg (600 mg for flat-dosing), flat-dosing resulted in higher median AUC0-24h compared to the weight-band dosing.
12 1 (95% Bayesian credible interval = 2.4-5.5), with a higher median but overlapping credible intervals compared with some
13                                                             Median C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L
14 riation across countries, with a resulting age-standardized median CFR of 1.9%.
15 %) completed the study: 806 in the negative pressure group (median duration of negative pressure, 4 days) and 802 in the
16                                    Among 45 responders, the median duration of response was 8.0 months (95% CI 6.5-14.7).
17                                                             Median estimated glomerular filtration rate (eGFR) was 43.7 m
18                                                             Median exposure (dose area product/kg) was decreased by 30% f
19                                                         The median extracorporeal membrane oxygenation support time was 9
20                                                      Over a median follow-up of 10.2 years, mortality was highest for myo
21                                                     After a median follow-up of 11 years (range 1 mo-25 yrs), symptomatic
22                                                        At a median follow-up of 12 months, the objective response rate to
23                                                     After a median follow-up of 3.1 years, the achieved LDL-C concentrati
24                                                      With a median follow-up of 44 months (26-53), 4-year event-free surv
25                       At the data cutoff (Aug 7, 2019), the median follow-up period was 12.9 months (IQR 6.2-22.9).
26                                                    During a median follow-up time of 62.5 months, 564 of the 3,478 partic
27                                                         The median follow-up was 59 months, and overall and major respons
28 nificantly associated with incident ASCVD (n = 1386 events; median follow-up, 25.2 years; hazard ratio [HR], 1.06 [95% CI
29                                                         The median injected activity of (18)F-rhPSMA-7 was 327 MBq (range
30  Spending on index surgery was significantly lower for EVR (median [interquartile range]: $25 924 [$22 280-$32 556] EVR v
31                                                             Median (IQR) concentration of plasma TMAO was 3.05 mumol/L (2
32                       One eye each of 97 glaucoma patients (median mean deviation, -2.31 dB) and 65 control participants
33                        Using an optimistic prior, posterior median odds ratios were 0.61 (95% credible interval, 0.41-0.9
34 w-up, 44% of YBMSM initiated PrEP through the study after a median of 122 days.
35 last histoplasmosis-associated healthcare visits occurred a median of 6 months after diagnosis.
36 fire models, including effects of land use and the ensemble median or mean compares better to observational datasets than
37                                                             Median overall survival was 57.1 months (95% CI 50-72) in the
38  identified among 1396 total preoperative MRI examinations (median patient age, 56 years; range, 25-94 years), resulting
39 5.1%; P = .005) and had less severe clinical presentations (median Pitt score, 0 [interquartile range {IQR} 0-1] vs 1 [IQ
40 achieved by 22 (71%) organs, that were transplanted after a median preservation time of 18 h, with 100% 90-day survival.
41    Adverse prognostic features of the cohort included short median PSA doubling time (2.3 mo) and extensive prior treatme
42 tumor control, preservation of serviceable hearing based on median pure tone averages (PTA), and procedure-related advers
43                     Anatomic structures were segmented, and median R2* values were calculated in the neocortex and cortic
44 nificant variation in rates across hospital sites (adjusted median rate, 11.4%; IQR, 8.9-14.5).
45                                                    Observed median steady-state TFV-DP was 965 fmol/punch (IQR:691, 1166)
46 y specific-activity, and antigen-site density most impacted median survival.
47                                                         The median SUV(max) across all lesions was 11.6 (range, 1.5-57.6)
48                                                             Median TTR for major respiratory pathogens by organism ranged
49                               Mean age was 74 years, with a median type 2 diabetes duration of 16 years.
50  of (18)F-rhPSMA-7 was 327 MBq (range, 132-410 MBq), with a median uptake time of 79.5 min (range, 60-153 min).